Kingdom of Spain (A19VKR) News

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm

21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in...

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Tempest to Participate in Upcoming Investor Conferences

BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported...

Form 8-K - Current report

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

BRISBANE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a...

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor...